REGENXBIO Discloses Going Concern Doubt, FDA Clinical Holds & CRL for Key Gene Therapies, and Securities Lawsuit

summarizeSummary

REGENXBIO faces substantial doubt about its ability to continue as a going concern, alongside critical FDA setbacks for its RGX-121 and RGX-111 gene therapies, and a new securities class action lawsuit.

check_boxKey Events · Legal and Risk Events · RGNX

• Going Concern Warning Issued

  Auditors express "substantial doubt" about the company's ability to continue operations for the next 12 months due to cumulative losses and cash outflows, highlighting the need for additional capital.

• FDA Clinical Holds and Complete Response Letter (CRL)

  The FDA placed clinical holds on both RGX-121 (MPS II) and RGX-111 (MPS I) programs in January 2026, and issued a CRL for the RGX-121 BLA in February 2026, citing concerns over study eligibility, control comparability, and surrogate endpoint appropriateness.

• Securities Class Action Lawsuit Filed

  A putative securities class action complaint was filed in February 2026, alleging the company misled investors regarding the viability and safety of its RGX-111 study, following the FDA's regulatory actions.

• Key Supplier Files for Bankruptcy

  Clearside Biomedical, the sole supplier of the SCS Microinjector used in REGENXBIO's Sura-vec retinal gene therapy programs, filed for Chapter 11 bankruptcy in November 2025, creating potential supply chain risks.

auto_awesomeAnalysis · RGNX · Life Sciences

The 10-K filing reveals REGENXBIO's auditors have raised "substantial doubt" about the company's ability to continue as a going concern, citing cumulative losses and cash outflows. This critical financial warning is compounded by significant setbacks in its gene therapy pipeline. The FDA issued clinical holds on both RGX-121 (MPS II) and RGX-111 (MPS I) programs in January 2026, followed by a Complete Response Letter (CRL) for the RGX-121 BLA in February 2026, questioning the study design and efficacy evidence. These regulatory hurdles directly impact the company's ability to commercialize these therapies and have led to a putative securities class action lawsuit. Additionally, a key supplier for its retinal program, Clearside Biomedical, filed for bankruptcy, introducing supply chain risks. While the company reported increased revenue from collaborations and pipeline progress in other areas, these severe challenges create a highly uncertain outlook for investors.